Oral delivery with novel solid dispersions: Stable self-assembled formulations of lipophilic drugs with improved bioperformance

Drug Delivery Technology

Volumn 9, Issue 7, 2009, Pages 36-43

  Krayz, Galia Temtsin ^a   Averbuch, Maryana ^a   Berman, Anna ^a   Zalcenstein, Amir ^a   Jaffe, Irene ^a  

^a SoluBest Formulation R and D ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; ALGINIC ACID; CARBOXYMETHYLCELLULOSE; CARRAGEENAN; CHITOSAN; COPOLYMER; CYCLODEXTRIN; DRUG CARRIER; ESTER DERIVATIVE; FENOFIBRATE; HYDROXYETHYLCELLULOSE; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; MACROGOL; MACROGOL DERIVATIVE; NANOPARTICLE; POLOXAMER; POLYACRYLIC ACID; POLYMER; POVIDONE; PROPYLENE GLYCOL; RESVERATROL; SOLU RESVERATROL; SOLUABZ; SOLUFENOFIBRATE; UNCLASSIFIED DRUG; VINYL ACETATE;

AREA UNDER THE CURVE; ARTERY INJURY; BIOTECHNOLOGY; CLINICAL TRIAL; CRYSTAL STRUCTURE; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG QUALITY; DRUG RELEASE; DRUG SOLUBILITY; EMULSION; HUMAN; HYDROPHILICITY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; METABOLIC SYNDROME X; MICELLE; MISCIBILITY; NEMATODIASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PARTICLE SIZE; PHYSICAL CHEMISTRY; REPRODUCIBILITY; REVIEW; SINGLE DRUG DOSE; TECHNIQUE;

EID: 70350714624     PISSN: 15372898     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (22)

1. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed & Pharmacother. 2004;58(3):173-182.
2. Hauss DJ, Fogal SE, Ficorilli JV, Price CA, Roy T, Jayaraj AA, Keirns JJ. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci. 2000;87(2):164-169. (Pubitemid 28081323)
3. Rangel-Yagui CO, Pessoa AJ, Tavares LC. Micellar solubilization of drugs. J Pharm Pharmaceut Sci. 2005;8(2):147-163.
4. Jones MC, Leroux JC. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm & Biopharm. 1999;48:101-111.
5. Szejtli J. Past, present, and future of cyclodextrin research. Pure Appl Chem. 2004;76(10):1825-1845.
6. Kesisoglou F, Panmai S, Wu Y. Nanosizing - oral formulation development and biopharmaceutical evaluation. Adv Drug Del Rev. 2007;39(7):631-644.
7. Müller RH, Kreck CM. Challenges and solution for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotech. 2004;113:151-170.
8. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Del Rev. 2004;56:335-347.
9. Good DJ, Rodriguez-Hornedo N. Solubility advantage of pharmaceutical cocrystals. Cryst Growth Des. 2009;9(5):2252-2264.
10. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm & Biopharm. 2000;50:47-60.
11. DiNunzio JC, Miller DA, McGinity JW, Williams RO. Formulating compositions to achieve enhanced oral bioavailability through supersatruration. Drug Delivery Technology. 2008;8(9):24-33.
12. Karanth H, Shenoy VS, Murthy RR. Industrially feasible alternative approaches in the manufacture of solid dispersions: a technical report. Pharm Sci Tech. 2007;7(4):87.
13. Temtsin KG, Averbuch M, Gitis L, Zelkind I. Composition comprising lopophilic active compounds and method for their preparation. Patent No. WO 2009/ 040818.
14. Parikh DM. Handbook of Pharmaceutical Granulation Technology. New York, Marcek Dekker: New York, NY;1997:77-78.
15. Lipson HH, Wooster WA. The Interpretation of X-ray Diffraction Photographs. N.F.M. Macmillan & Co.: New York, NY;1961.
16. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nature Rev. 2006;5:493-506.
17. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G, Goldberg DM. The red wine phenolics trans-reveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clin Chim Acta. 1995;235(2):207-219.
18. Zou JG, Wang ZR, Huang YZ, Cao KJ, Wu JM. Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int J Mol Med. 2003;11(3):317-320.
19. Jang JH, Surh YJ. Protective effect of resveratrol on beta-amyloid induced oxidative PC12 cell death. Free Radic Biol Med. 2003;34(8):1100-1110. (Pubitemid 36398570)
20. Cal C, Garban H, Jazirehi A, Yeh C, Mizutani Y, Bonavida B. Resveratrol and cancer: chemoprevention , apoptosis, and chemoimmunosensitizing activities. Curr Med Chem-Anti-Cancer Agents. 2003;3(2):77-93. (Pubitemid 36221731)
21. Wang Y, Catana F, Yang Y, Roderick R, Richard B, van Breemen RB. An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem. 2002;50(3):431-435. (Pubitemid 34106659)
22. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavaiability of oral resveratrol in humans. Drug Metab & Disp. 2004;32(12):1377-1382. (Pubitemid 39564557)